Similarly, HIF3A (Hypoxia Inducible Factor 3 Alpha) likely contributes to the hypoxic adaptation that characterizes aggressive gliomas, promoting treatment resistance and accelerated disease progression (Monteiro et al., 2017). Here, HIF3A is linked to central nervous system cancer.